Vertex rises after kidney disease drug shows promise in mid-stage study

By Reuters News

** Shares of Vertex Pharmaceuticals VRTX.O rise 1.1% to $516.53

** The biotech firm says its experimental drug inaxaplin cut protein in urine, a key sign of kidney damage, by 42.7% after 13 weeks in patients with APOL1-mediated kidney disease

** The genetic kidney disorder mainly affects people of African ancestry and can lead to kidney failure; no approved therapies exist

** Co says the drug also cut protein levels by 17.3% in patients who had both the disease and type 2 diabetes

** Says inaxaplin was generally safe and well tolerated, with no treatment-related serious side effects

** Including session's move, stock up ~14% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.